Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Mediqstar closes a pre-Series B funding round from Genaxis to accelerate overseas commercialization of its AI-powered TB diagnostic platform. The amount raised was not disclosed.

PRIVATEAug 03, 2026•6 days ago

Round Type

Series B

South KoreaBiotechnologyHealth CareArtificial IntelligenceMedicalMedical DeviceMachine LearningHealth Diagnostics

Investors

Genaxis

Description

Mediqstar, a South Korean medical AI startup, has completed a pre-Series B funding round with Genaxis as the sole investor. The new capital will be used to advance the commercialization of its tuberculosis diagnostic solution, MycoScan, and R&D for colorectal cancer diagnostics. Genaxis decided to provide follow-on capital after evaluating Mediqstar’s technology and commercialization potential. MycoScan has received medical device approval in Korea and aims to enhance TB diagnostics.

Company Information

Company

Mediqstar

Location

South Korea

About

Mediqstar is a South Korean startup specializing in medical AI and large language models. It has developed MycoScan, an AI-powered tuberculosis diagnostic microscopy platform that operates in standard environments without the need for high-performance GPU servers. The company is expanding into colorectal cancer diagnostics with an integrated medical AI system using advanced data analysis techniques. Mediqstar is actively pursuing business partnerships in regions with high TB prevalence to expand its impact.

Predictive Intelligence
Strategic

ML-powered predictions for Mediqstar's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.